Medscape2y
Intravitreal Injections and Endophthalmitis
The rapid growth in IVT injections ... recent outbreaks of endophthalmitis have occurred in cities across the United States due to compounded bevacizumab and triamcinolone, which has raised ...
Ophthalmology Times3d
4DMT announces positive 52-week data from phase 2b cohort of PRISM wet AMD study
PRISM evaluates 4D-150, a potential backbone therapy designed to provide multi-year sustained delivery of anti-VEGF ...
The American Journal of Managed Care8d
FDA Approves Ranibizumab Implant in Treatment of DME
The ranibizumab injection delivered through an implant device could be administered in a convenient schedule twice per year ...
Ophthalmology Times8d
FDA approves continuous delivery ranibizumab injection (Susvimo) for the treatment of diabetic macular edema
Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...
Morningstar9d
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Intravitreal injections, including those with Lucentis, have been associated with endophthalmitis, retinal detachment, and iatrogenic traumatic cataract. Increases in intraocular pressure have ...
Medscape19d
Ocular Hypertension Following Intravitreal Antivascular Endothelial Growth Factor Therapy
Intravitreal injections of anti-VEGF agents have become an important tool in the management of some of the most common retinal and choroidal neovascular diseases. Adverse effects are uncommon ...